Recommendations for Use of Certican® (Everolimus) After Heart Transplantation: Results From a German and Austrian Consensus Conference
- 1 April 2005
- journal article
- review article
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 24 (4) , S196-S200
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Therapeutic Drug Monitoring for Everolimus in Heart Transplant Recipients Based on Exposure–Effect ModelingAmerican Journal of Transplantation, 2004
- Everolimus (Certican) 12-Month Safety and Efficacy Versus Mycophenolate Mofetil in de Novo Renal Transplant RecipientsTransplantation, 2004
- Optimizing the immunosuppressive regimen in heart transplantationThe Journal of Heart and Lung Transplantation, 2004
- Everolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6-Month Safety and Efficacy Results of Two Randomized StudiesAmerican Journal of Transplantation, 2004
- Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant RecipientsNew England Journal of Medicine, 2003
- One-year results of an international, randomized, double-blind study of everolimus vs azathioprine as adjunctive therapy to inhibit the decline of pulmonary function in stable lung or heart/lung transplant recipientsThe Journal of Heart and Lung Transplantation, 2003
- Monitoring of cyclosporine 2-hr post-dose and trough levels in heart transplantationThe Journal of Heart and Lung Transplantation, 2002
- Population pharmacokinetics of everolimus in de novo renal transplant patients: Impact of ethnicity and comedicationsClinical Pharmacology & Therapeutics, 2001
- CLINICAL BENEFIT OF NEORAL DOSE MONITORING WITH CYCLOSPORINE 2-HR POST-DOSE LEVELS COMPARED WITH TROUGH LEVELS IN STABLE HEART TRANSPLANT PATIENTS1Transplantation, 1999
- NEORAL MONITORING BY SIMPLIFIED SPARSE SAMPLING AREA UNDER THE CONCENTRATION-TIME CURVETransplantation, 1999